Funding rounds, M&A, IPOs, and market analysis—where capital is flowing and why the tape moves.
Digital health sector investment reached $7.4 billion in H1 2026, but with AI solutions becoming commonplace, the competitive edge is shifting from technology to deep domain expertise.
Digital health sector investment reached $7.4 billion in H1 2026, but with AI solutions becoming commonplace, the competitive edge is shifting from technology to deep domain expertise.
READ MORE
Handspring has raised $19 million in Series B funding to expand its innovative pediatric mental health care model, designed to fill the 'missing middle' between low- and high-acuity support for youth.
IKS Health’s acquisition of TruBridge, a company specializing in EHR and revenue cycle solutions for rural hospitals, marks its third deal this year as it integrates advanced technology into its AI-driven care platform.
Vertex Pharmaceuticals' recent high-profile deal and a growing appetite for biopharma M&A signal shifting tides in 2026. The company’s acquisition activity comes alongside an uptick in IPOs and venture capital raises, even as FDA decision-making faces administration uncertainties.
A new report details how private equity firms are increasingly engaging in joint ventures with nonprofit health systems to gain a greater foothold in the healthcare sector, prompting debates over transparency and oversight.
The escalating costs of American healthcare continue to spark debate, but a core question often goes unasked: What level of healthcare system capacity is truly necessary, and what results should society expect for its investment? Delving into this foundational issue can reframe the ongoing conversation.
Serapha Bio completes a $230 million reverse merger with Boundless Bio to focus on gene-editing treatments for alpha-1 antitrypsin deficiency, reflecting the growing momentum and complexity of cross-border life sciences deals and next-generation genetic medicine.
Cadence, an AI-powered chronic care platform, secures $100 million in Series C funding to expand its solution for real-time patient monitoring and medication management at home.
InStride has secured $30 million in Series C financing to bolster its pediatric mental health services, gaining wide backing from prominent investors. The funding comes as rising rates of mental health issues among children present an urgent challenge for healthcare systems nationwide.
Parabilis Medicines is preparing for an IPO that could raise as much as $637 million, potentially setting a new bar for biotech public offerings during a period of sector-wide uncertainty.
CereVasc raised $85 million to propel the development of its innovative eShunt system, designed to treat hydrocephalus without the need for traditional brain shunt surgery.
